NGS Strategies for Vaccine Development and Surveillance of Respiratory Viruses

Life Sciences, Laboratory Technology, Fundamental Research,
  • Wednesday, May 01, 2024 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
  • 60 min

In the landscape of infectious diseases, next-generation sequencing (NGS) has emerged as a transformative technology, offering unparalleled insights into the complex dynamics of respiratory RNA viruses and critical gene sequences associated with viral infection. This webinar delves into the multifaceted applications of NGS, spanning from viral typing and targeted gene sequencing to whole-genome analysis, with a particular focus on its utility in outbreak tracing and clinical diagnostics.

In this webinar, the expert speaker addresses the inherent challenges associated with analyzing low viral load clinical samples and offers strategies to enhance sensitivity and specificity in NGS-based assays. By leveraging whole-genome sequencing (WGS), NGS enables the simultaneous detection of multiple viral strains within a single sample, shedding light on the complex interplay between different pathogens and their implications for clinical management and public health interventions.

The attendees will gain insights into the intricacy of NGS assay development and validation where considerations such as workflow optimization and methodological choices, including probe-based versus amplicon sequencing, play pivotal roles in ensuring the accuracy and reliability of results.

The expert speaker will also provide a comprehensive overview of NGS tactics for analyzing respiratory RNA viruses and key gene sequences, thus highlighting their role in guiding clinical management, surveillance efforts and outbreak control measures.

Register for this webinar today to gain insights into NGS sequencing techniques tailored for analyzing respiratory RNA viruses with a focus on vaccine development.

Speaker

Kirthi Kumar Kutumbaka, Viracor Biopharma Services

Kirthi Kumar Kutumbaka, PhD, Scientific Manager, Research & Development, Eurofins Viracor Biopharma Services

Dr. Kirthi Kumar Kutumbaka joined Eurofins Viracor Biopharma Services in 2021, assuming the role of Senior Scientist in Kansas City, Kansas. Currently serving as a Scientific Manager for Research & Development, he leads technical initiatives focused on assay development and validation. Dr. Kutumbaka’s expertise lies in leveraging cutting-edge technologies, including next-generation sequencing (NGS), Sanger sequencing, ddPCR and Nanostring nCounter platforms, to advance research objectives.

With over a decade of experience in the life sciences industry and more than 15 years in research & development, Dr. Kutumbaka brings a wealth of expertise to his current role. He holds a PhD in Microbiology and a Master’s degree in Bioinformatics from Northern Illinois University in Dekalb, IL.

During his tenure as a Post-Doctoral Researcher and Research Scientist at IEH Laboratories and Consulting Group, Dr. Kutumbaka made significant contributions to various foodborne outbreak investigations. His application of NGS technologies played a crucial role in elucidating the genetic diversity of pathogens involved in these outbreaks.

Message Presenter

Who Should Attend?

This webinar will appeal to:

  • Researchers and Scientists involved in virology, molecular biology and infectious disease research, particularly those focused on respiratory RNA viruses
  • Public health professionals and Epidemiologists interested in understanding the dynamics of viral outbreaks and implementing surveillance strategies
  • Vaccine developers and Immunologists seeking insights into viral diversity, pathogenesis and potential vaccine targets

What You Will Learn

Attendees will learn about:

  • NGS advancements for respiratory viruses: Discover cutting-edge advancements in next-generation sequencing (NGS) techniques tailored for analyzing respiratory RNA viruses, offering insights into viral diversity and evolution
  • Vaccine insights through NGS: Learn how NGS enhances vaccine development efforts by uncovering crucial information on viral diversity, evolution and potential vaccine targets essential for effective immunization strategies

Xtalks Partner

Eurofins Clinical Trial Solutions

Complex innovative clinical trial designs require an integrated synergetic approach to assess novel drug compounds for safety and effectiveness which often span esoteric, regulated and safety outcomes in all phases of the drug development life cycle. The companies of Eurofins Bioanalytical Services, the Eurofins Central Laboratory global network, Eurofins Viracor BioPharma Services, and Eurofins Clinical Trial Supplies are building a stronger connection to provide a seamless solutions-based approach to our client needs. Eurofins Clinical Trial Solutions provides seamless, end-to-end solutions to help clients progress through the drug development cycle through a single, experienced provider. Our integrated solutions deliver the most comprehensive range of state-of-the-art analytical technologies with an expansive geographic reach in order to support our clients’ specialized testing needs and stringent quality and safety requirements around the world.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account